Development of Varicella Vaccine

Takahashi, Michiaki; Asano, Yoshizo; Kamiya, Hitoshi; Baba, Koichi; Ozaki, Takao; Otsuka, Terumasa; Yamanishi, Koichi
March 2008
Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS41
Academic Journal
The Oka strain of varicella-zoster virus (VZV) was first isolated from vesicles of an otherwise healthy 3-year- old boy with typical varicella. The virus was passaged 11 times in human embryonic lung fibroblasts at 34°C and 12 times in guinea pig embryo fibroblasts (GPEFs) at 37°C. GPEFs were the only nonprimate cells tested in which some degree of viral replication occurred. The resultant virus was temperature sensitive and showed host dependency, measured as better replication in GPEFs than that shown by the parental virus. The passaged virus was used as a candidate varicella vaccine and proved safe and effective for healthy and immunocompromised children. During the follow-up of vaccinated children with acute lymphocytic leukemia, the incidence of herpes zoster (HZ) was significantly lower among children who did not have a rash after vaccination, compared with those who had a rash caused by VZV (6 [2.3%1 of 260 vs. 12 [17.1%] of 70, respectively). Because of the pathogenesis of VZV, the incidence of latency and of HZ is predicted to be lower among vaccine recipients than among individuals who have experienced varicella.


Related Articles

  • Perspective on Live Varicella Vaccine. Gershon, Anne A.; Katz, Samuel L. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS242 

    The attenuation of varicella-zoster virus (VZV) by Takahashi in 1974 was a remarkable achievement. It swiftly led to development of a live vaccine against chickenpox, which was initially tested in Japan. With its successful employment in immunocompromised children to prevent morbidity and...

  • Varicella Vaccination of Immunocompromised Children. Levin, Myron J. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS200 

    Background. Exposure of immunocompromised children to varicella often requires postexposure prophylaxis. Exposures requiring this management are often not recognized. Varicella can he a severe disease when it occurs in immunocompromised children, in spite of antiviral therapy. Varicella exposure...

  • Vaccine Oh Variants and Sequence Variability in Vaccine-Related Skin Lesions. Breuer, Judith; Scott Schmid, D. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS54 

    As with most live attenuated viral vaccines, varicella vaccine comprises a mixture of variant strains. Knowledge about the pathogenic potential of individual strains in the varicella vaccine is limited. Vaccination against chickenpox causes a usually modified varicella-like rash in a small...

  • The Impact of Varicella Vaccination on Herpes Zoster in Children. Jenson, Hal B. // Infectious Disease Alert;Sep2009, Vol. 28 Issue 12, p133 

    A POPULATION-BASED TELEPHONE SURVEY WAS CONDUCTED among residents < 20 years of age in Antelope Valley, CA, from 2000 through 2006. During this period, 459 evaluable cases of herpes zoster among persons < 20 years of age were reported. Of these cases, 154 (34%) were among children < 10 years of...

  • Varicella Immunogenicity with 1- and 2-Dose Regimens of Measles-Mumps-Rubella-Varicella Vaccine. Shinefield, Henry R.; Black, Steve; Kuter, Barbara J. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS152 

    A quadrivalent vaccine combining measles, mumps, rubella, and varicella antigens (MMRV) was developed to increase the coverage of varicella vaccine and reduce the number of injections children receive. Although the varicella antigen is as immunogenic in the latest formulation of MMRV vaccine as...

  • Humoral and Cell-Mediated Immune Responses in Children and Adults after 1 and 2 Doses of Varicella Vaccine. Watson, Barbara // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS143 

    Humoral and cell-mediated immune responses to varicella-zoster virus (VZV) have been evaluated after 1 and 2 doses of live attenuated varicella vaccine, Oka strain, in several studies. One dose of varicella vaccine, however, elicits detectable immune responses that are low and, in some cases,...

  • An Economic Analysis of the Universal Varicella Vaccination Program in the United States. Fangjun Zhou; Ortega-Sanchez, Ismael R.; Guris, Dalya; Shefer, Abigail; Lieu, Tracy; Seward, Jane F. // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS156 

    Frequent varicella outbreaks with sizable impact on the US public health system have continued to occur despite the success of the country's 1-dose varicella vaccination program. The Advisory Committee on Immunization Practices recently recommended adding a routine second dose of varicella...

  • Risk for Zoster from the Vaccine in Immunosuppressed Persons. Kuritzky, Louis // Neurology Alert;Sep2012, Vol. 31 Issue 1, p17 

    The article discusses research on the real-life risk of an acute zoster infection after herpes zoster vaccine (ZOS), referencing the study "Risk for Zoster From the Vaccine in Immunosuppressed Persons" by J. Zhang in a 2012 issue of the "Journal of the American Medical Association."

  • Varicella Vaccine Effectiveness in the US Vaccination Program: A Review. Seward, Jane F.; Mann, Mona; Vázquez, Marietta // Journal of Infectious Diseases;Mar2008 Supplement 2, Vol. 197, pS82 

    Varicella vaccine (Varivax, Merck) has been available in the United States since 1995. We reviewed published results of postlicensure studies of vaccine effectiveness. Among 19 studies, 17 reported on the effectiveness of vaccine received before exposure, and 2 reported on effectiveness after...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics